3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
BRAF V600E Mutation
1
Interventions
Cyclophosphamide
43
venetoclax
30
Cytarabine
25
fludarabine
22
fludarabine phosphate
17
Azacitidine
16
Mycophenolic Acid
13
Whole-Body Irradiation
12
Dexamethasone
12
ruxolitinib
11
Rituximab
11
Busulfan
11
Vincristine
10
Methotrexate
10
Etoposide
10
Tacrolimus
9
Daunorubicin
9
Mercaptopurine
8
Filgrastim
8
Dasatinib
8
ibrutinib
7
Prednisone
7
Peripheral Blood Stem Cell Transplantation
7
Melphalan
7
Granulocyte Colony-Stimulating Factor
7
Doxorubicin
7
Decitabine
7
pegaspargase
6
blinatumomab
6
Mesna
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
Cobicistat
×
1 year
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA